Kamada Ltd. (KMDA) Insider Trading Activity

NASDAQ$8.09
Market Cap
$466.64M
Sector
Healthcare
Industry
Drug Manufacturers—Specialty & Generic
Rank in Sector
612 of 843
Rank in Industry
31 of 46

KMDA Insider Trading Activity

KMDA Median Price and Trade Amounts History Chart

Statistics of Insider Transactions

Amount of Insider Buys and Sells

Buys
$0
0
0
Sells
$1,650,459
4
100

Related Transactions

Tsur Daviddirector
0
$0
4
$1.65M
$-1.65M

About Kamada Ltd.

Kamada Ltd. is a biopharmaceutical firm focused on developing, manufacturing, and distributing protein therapeutics derived from human plasma. The company operates through two core business areas: its proprietary product segment and its distribution division. Its own manufactured portfolio includes KAMRAB/KEDRAB for rabies prevention, CYTOGAM to prevent cytomegalovirus disease in transplant recipients, WINRHO SDF for immune thrombocytopenic purpura and Rhesus (Rh) isoimmunization, HEPAGAM B for hepatitis B recurrence prevention following liver transplants and for post-exposure prophylaxis, VARIZIG for post-exposure chickenpox prophylaxis, and GLASSIA for intravenous alpha-1 antitrypsin deficiency (AATD). Kamada also produces KamRho (D) for the prophylaxis of hemolytic disease of newborns and immune thrombocytopenic purpura, along with a specific antiserum for Vipera palaestinae and Echis coloratus snake bites. Additionally, the company distributes a wide array of third-party pharmaceutical products, encompassing treatments like BRAMITOB for chronic pulmonary infections, FOSTER for asthma, PROVOCHOLINE for diagnosing bronchial airway hyperactivity, and specialized therapies such as IVIG for immunodeficiency, VARITECT for chickenpox and zoster herpes, and various factors for hemophilia A and B, among numerous others for conditions like hepatitis B, cytomegalovirus, angioedema, Japanese encephalitis, and prostate cancer. Kamada markets its offerings in the United States through strategic partners and internationally via a network of distributors. The company maintains significant collaborations with Takeda Pharmaceuticals Company Limited, PARI GmbH, and Kedrion Biopharma. Established in 1990, Kamada Ltd. is headquartered in Rehovot, Israel.

Insider Activity of Kamada Ltd.

Over the last 12 months, insiders at Kamada Ltd. have bought $0 and sold $1.65M worth of Kamada Ltd. stock.

On average, over the past 5 years, insiders at Kamada Ltd. have bought $0 and sold $1.65M worth of stock each year.

There was no buying activity among insiders over the last 12 months.

List of Insider Buy and Sell Transactions, Kamada Ltd.

2026-09-14SaleTsur Daviddirector
22,827
0.0388%
$8.18
$186,725
-3.73%
2026-09-09SaleTsur Daviddirector
175
0.0003%
$8.26
$1,446
-2.56%
2026-09-08SaleTsur Daviddirector
162,760
0.2801%
$8.26
$1.34M
-3.50%
2026-09-07SaleTsur Daviddirector
14,238
0.0238%
$8.28
$117,891
-3.50%
Total: 4
*Gray background shows transactions not older than one year

KMDA Institutional Investors: Active Positions

Increased Positions32+72.73%484,560+8.11%
Decreased Positions19-43.18%1M-17.87%
New Positions11New68,733New
Sold Out Positions10Sold Out843,872Sold Out
Total Postitions57+29.55%5M-9.75%

KMDA Ownership Change vs Market

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders

Financial Ratios

Summary
Comparison with Competitors

Price to Earnings

Price/Earnings to Growth

Price to Sales

Price to Book

Price/Free Cash Flow

Analyst Recommendations

Analyst Price Targets

Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.